Positron Emission Tomography Markets

The medical imaging segments are poised for a major new phase of growth fueled by the availability of new technology coming out of the computer and digital information technology segment. Continuous improvements in technology are resulting in a growing number of new imaging tests that combine high levels of accuracy with rapid, easy-to-use product formats. Part of that medical imaging improvement is coming from positron emission tomography (PET). PET is a scanning technique used in combination with small amounts of radio-labeled compounds to visualize the anatomy and function of the brain. The purpose of this TriMark Publications report is to describe the specific market segment of the diagnostics medical imaging market called PET scanning. This sector includes all of the generally accepted imaging activities that are currently used in PET, including equipment for PET, PET/CT, SPECT and the use of radiopharmaceuticals for imaging. It examines these clinical measurement devices and their reagents and supplies as used in hospitals and clinics. It also reviews associated clinical market segments in which PET scanning has taken a prominent role including cancer treatment, cardiology and neurology imaging markets.

TABLE OF CONTENTS 



1 Overview 4

1.1 Statement of Report 4

1.2 Scope of this Report 4

1.3 Methodology 5

1.4 Executive Summary 7



2 Overview of the Medical Imaging Market 9

2.1 Medical Imaging Industry Market Size 9

2.2 Medical Imaging Infrastructure 10

2.2.1 Total Healthcare Expenditures and Demographics 10

2.2.2 Number of Hospitals 12

2.2.3 Number of Radiologists 14

2.2.4 Radiologic Services 15

2.2.5 Medical Imaging Companies 17

2.2.6 Medical Imaging Market Drivers 17

2.2.7 Market Restraints 18

2.2.8 Market Segments for PET Imaging 19

2.2.9 Key Players in the PET Imaging Segment 24

2.2.10 Medical Imaging Sector Analysis 26

2.3 Structure and Use of PET Imaging 27

2.3.1 Functional Imaging versus Anatomic Imaging 27

2.3.2 Functional Imaging Using Single-photon Imaging (SPECT) 28

2.3.3 PET in Clinical Use 31

2.3.4 PET Sensitivity 32

2.3.5 Therapeutic Uses of PET 32

2.3.6 PET/CT 32

2.3.7 The Future of PET in Cancer Imaging 33

2.3.8 PET Reimbursement 33

2.4 Radiopharmaceutical Imaging 34

2.4.1 Cardinal Health Acquires PET Radiopharmaceutical Production Facilities 35

2.4.2 GE Healthcare Launches New Platform for Automated Synthesis of PET Radiopharmaceuticals 35

2.4.3 Siemens Medical PETNET Radiopharmacy 36

2.4.4 Future Growth of PET Imaging Procedures 36

2.4.5 Diagnostic Radiopharmaceuticals: Market Analysis and Future Prospects 37

2.4.6 New Radiopharmaceutical Applications 37



3 PET Market 39

3.1 Market Size 39

3.2 Total PET and PET/CT Market Trends 39

3.2.1 Market Segmentation and Definitions 39

3.2.2 Overview 40

3.2.3 Market Measurements 40

3.2.4 Market Drivers 42

3.2.5 Market Restraints 43

3.3 Total PET and PET/CT Market Forecasts 43

3.3.1 Revenue Forecasts 43

3.3.2 Unit Shipment Forecasts 44

3.3.3 Procedure Forecast 45

3.3.4 Competitive Structure 46

3.3.5 Market Share Analysis 48

3.3.6 Future Directions for PET 50

3.3.7 New PET Technology Platforms 51

3.4 SPECT Market Forecasts 51

3.4.1 Revenue Forecasts 52

3.4.2 Unit Shipment Forecasts 52

3.4.3 Market Share Analysis 52

3.5 PET/CT Market Forecasts 52

3.5.1 PET/CT Revenue Forecasts 53

3.5.2 PET/CT Unit Shipment Forecasts 53

3.5.3 PET/CT Market Share Analysis 53

3.6 Products 54

3.6.1 Gamma Medica 54

3.6.2 Mallinckrodt 54

3.6.3 Naviscan PET Systems 54

3.6.4 Siemens 54

3.6.5 TeraRecon 54

3.6.6 Toshiba America Medical Systems 54

3.6.7 CTI Molecular Imaging Inc. 54

3.6.8 GE Healthcare 55

3.6.9 Philips Medical Systems 55

3.7 Manufacturers 55



4 PET/CT 57

4.1 Strengths of CT and PET Scanning 57

4.2 Combining CT’s Strengths with PET Scanning 57

4.3 Nuclear Medicine Safety Protocols 58

4.4 PET Safety Protocols 59

4.4.1 Radiation Safety 60

4.4.2 Appropriate Shielding 61

4.4.3 Radioactive Package Protocols 62

4.5 Regulatory Requirements 64

4.6 PET and SPECT Tracers 64

4.7 PET Imaging 65

4.8 PET and Cancer Staging 65



5 Hybrid Technology: PET/CT and SPECT/CT 67

5.1 PET/CT 67

5.2 SPECT/CT 67

5.2.1 Blending of Technology Platforms 68

5.2.2 SPECT vs. PET 69



6 SPECT and SPECT/CT 71

6.1 Single Photon Emission Computed Tomography (SPECT) 71

6.1.1 SPECT Imaging 71

6.2 SPECT/CT 72

6.3 Potential Applications of SPECT/CT 73

6.4 New Technology Platforms: SPECT 76



7 Clinical PET/CT for Oncology Applications 77

7.1 Pulmonary Nodules 77

7.2 Non–Small-Cell Lung Cancer 77

7.3 Melanoma 78

7.4 Lymphoma 78

7.5 Colorectal Cancer 79

7.6 Head and Neck Cancer 79

7.7 Esophageal Cancer 80

7.8 Breast Cancer 80

7.9 Brain Cancer 81

7.10 Prostate Cancer 82

7.11 Ovarian Cancer 82

7.12 Cervical Cancer 83

7.13 Testicular Cancer 83

7.14 Thyroid Cancer 83

7.15 Pancreatic Cancer 83

7.16 Trends in Clinical Use of PET/CT 83

7.17 Development of PET/MRI 83



8 Company Profiles 85



Appendix 1. Radiopharmaceutical Diagnostic Imaging Agents Codes and PET Scan Services 86





LIST OF TABLES



Table 2.1: U.S. Medical Imaging Market Size, 2001 to 2010 10

Table 2.2: Global Medical Imaging Market Size, 2001 to 2010 10

Table 2.3: U.S. Healthcare Expenditures, 1999 to 2010 11

Table 2.4: U.S. Health Expenditures as a Percentage of GDP, 1998 to 2010 11

Table 2.5: U.S. User Expenditures for Medical Imaging Equipment and Related Products 11

Table 2.6: Comparison of Spending on Health by Country, 2003 11

Table 2.7: Spending on Health by Country 12

Table 2.8: Millions of Americans Over 65 Years of Age, 2000 to 2050 12

Table 2.9: Public and Private Healthcare Expenditures, 1960 to 2000 12

Table 2.10: Hospital Survey 13

Table 2.11: U.S. Radiological Images Taken, 1999 to 2010 13

Table 2.12: Percent Change in Volume of Examinations per Imaging Modality between 1993 and 2004 16

Table 2.13: Worldwide Market Share Medical Imaging and Diagnostic Companies 17

Table 2.14: U.S. Nuclear Medicine Procedures, 2002 to 2010 20

Table 2.15: PET Radioisotopes 34

Table 3.1: Type of Imaging Offered by Facility 39

Table 3.2: PET Procedures by Type 41

Table 3.3: U.S. Dollar Sales of PET Imaging Systems, 2004 to 2011 43

Table 3.4: Worldwide Dollar Sales of PET Imaging Systems, 2004 to 2011 44

Table 3.5: Unit Sales of PET Imaging Systems, 2004 to 2011 44

Table 3.6: PET Procedure Volume, 2004 to 2011 45

Table 3.7: FDG Sales, 2004 to 2011 46

Table 3.8: SPECT Procedure Volume, 2004 to 2011 52

Table 3.9: U.S. SPECT Scanner Market Size and Growth, 2002 to 2010 52

Table 3.10: U.S. PET/CT Scanner Market Size and Growth, 2002 to 2010 53

Table 5.1: SPECT and PET Hybrid Sales Percentages 68